Historical valuation data is not available at this time.
Aptorum Group Limited is a biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs, particularly in oncology, infectious diseases, and metabolic disorders. The company operates through its subsidiaries, leveraging a hybrid business model that combines drug discovery with licensing and partnerships. Aptorum’s pipeline includes repurposed drugs and new molecular entities, targeting diseases with high unmet needs. The company is listed on Euronext Paris but maintains a relatively small market presence compared to larger biopharma peers.
Focus on repurposing existing drugs and developing new therapeutics; holds patents for select pipeline candidates.
Aptorum Group presents high-risk, high-reward potential given its early-stage pipeline and focus on unmet medical needs. The lack of near-term revenue and reliance on clinical success pose significant risks. Investors should monitor trial progress and partnership announcements closely. Only suitable for those with high risk tolerance.
Aptorum Group investor presentations, Euronext Paris filings, company website.